With two new drugs approved by the FDA, the National Plan to End Parkinson’s signed into law and many advances in our understanding of Parkinson’s disease, 2024 has been a transformative year in Parkinson’s research. Tune into audio from this month’s Third Thursdays Webinar to hear research experts from industry and academia talk with MJFF staff about the latest research on disease biology and emerging therapies.
If you’d rather listen on the go, subscribe to our Michael J. Fox Foundation’s Parkinson’s Podcast on iTunes or your preferred podcast app. If you enjoyed what you heard, share it with a friend or leave a review! It helps listeners like you find and support our mission.
In this episode Maggie Kuhl, vice president of patient engagement at The Michael J. Fox Foundation (MJFF), leads a conversation with:
- Maurizio Facheris, MD, chief medical officer at Vanqua Bio.
- Thomas Tropea, DO, MPH, MSTR, chief medical officer at The Institute for Neurodegenerative Disorders.
- Todd Sherer, PhD, chief mission officer at MJFF.
View a transcript of the podcast.
Read more about this year in research.
The Foundation’s landmark study, the Parkinson’s Progression Markers Initiative, also known as PPMI, is recruiting volunteers. Join the study that’s changing everything.